CN114948852A - 一种用于脑部疾病诊断和治疗的微针系统及其制备方法 - Google Patents
一种用于脑部疾病诊断和治疗的微针系统及其制备方法 Download PDFInfo
- Publication number
- CN114948852A CN114948852A CN202210589807.8A CN202210589807A CN114948852A CN 114948852 A CN114948852 A CN 114948852A CN 202210589807 A CN202210589807 A CN 202210589807A CN 114948852 A CN114948852 A CN 114948852A
- Authority
- CN
- China
- Prior art keywords
- active drug
- liposome
- parts
- microneedle
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 208000014644 Brain disease Diseases 0.000 title claims abstract description 37
- 238000003745 diagnosis Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 134
- 239000002502 liposome Substances 0.000 claims abstract description 117
- 229940079593 drug Drugs 0.000 claims abstract description 114
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000002270 dispersing agent Substances 0.000 claims abstract description 14
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 13
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000000265 homogenisation Methods 0.000 claims abstract description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 92
- 229940109262 curcumin Drugs 0.000 claims description 46
- 235000012754 curcumin Nutrition 0.000 claims description 46
- 239000004148 curcumin Substances 0.000 claims description 46
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 26
- 239000011259 mixed solution Substances 0.000 claims description 26
- 239000011664 nicotinic acid Substances 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 210000000822 natural killer cell Anatomy 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 102000018697 Membrane Proteins Human genes 0.000 claims description 9
- 108010052285 Membrane Proteins Proteins 0.000 claims description 9
- 238000010025 steaming Methods 0.000 claims description 9
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000010257 thawing Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 claims description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- -1 colloidan Chemical compound 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000004417 polycarbonate Substances 0.000 claims description 6
- 229920000515 polycarbonate Polymers 0.000 claims description 6
- 238000002203 pretreatment Methods 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 5
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 4
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 4
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 claims description 4
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004536 betahistine Drugs 0.000 claims description 4
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims description 4
- 229960000326 flunarizine Drugs 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229960000715 nimodipine Drugs 0.000 claims description 4
- 229960001789 papaverine Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 229960000744 vinpocetine Drugs 0.000 claims description 4
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 3
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 3
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004538 alprazolam Drugs 0.000 claims description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003805 amantadine Drugs 0.000 claims description 3
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 3
- 229960005174 ambroxol Drugs 0.000 claims description 3
- 229950005197 butylphthalide Drugs 0.000 claims description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 3
- 229960000623 carbamazepine Drugs 0.000 claims description 3
- 229960001653 citalopram Drugs 0.000 claims description 3
- 229960003529 diazepam Drugs 0.000 claims description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 3
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims description 3
- 229960002870 gabapentin Drugs 0.000 claims description 3
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 3
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 3
- 229960001848 lamotrigine Drugs 0.000 claims description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 3
- 229960004002 levetiracetam Drugs 0.000 claims description 3
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 3
- 229960004391 lorazepam Drugs 0.000 claims description 3
- 229960002640 nordazepam Drugs 0.000 claims description 3
- AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 claims description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 3
- 229960005017 olanzapine Drugs 0.000 claims description 3
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004535 oxazepam Drugs 0.000 claims description 3
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960001816 oxcarbazepine Drugs 0.000 claims description 3
- 229960002790 phenytoin sodium Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229960005197 quetiapine fumarate Drugs 0.000 claims description 3
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 3
- 229960000245 rasagiline Drugs 0.000 claims description 3
- 229960003312 retigabine Drugs 0.000 claims description 3
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 3
- 229960001879 ropinirole Drugs 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 3
- 229960003946 selegiline Drugs 0.000 claims description 3
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims description 3
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960004603 tolcapone Drugs 0.000 claims description 3
- 229960004394 topiramate Drugs 0.000 claims description 3
- 229960003386 triazolam Drugs 0.000 claims description 3
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- FROZIYRKKUFAOC-UHFFFAOYSA-N amobam Chemical compound N.N.SC(=S)NCCNC(S)=S FROZIYRKKUFAOC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 229960001233 pregabalin Drugs 0.000 claims description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 claims 1
- SDWAACKJISOIGZ-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one;2,2,2-trichloroethane-1,1-diol Chemical compound OC(O)C(Cl)(Cl)Cl.N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SDWAACKJISOIGZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002767 ethosuximide Drugs 0.000 claims 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 1
- 229960004653 midazolam maleate Drugs 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
- 229960002911 zonisamide Drugs 0.000 claims 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000013271 transdermal drug delivery Methods 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 20
- 239000002245 particle Substances 0.000 description 12
- 230000003592 biomimetic effect Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 239000008055 phosphate buffer solution Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940084026 sodium valproate Drugs 0.000 description 3
- 108010022355 Fibroins Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 2
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 2
- 229960002414 ambrisentan Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000002418 meninge Anatomy 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 2
- 229960005318 vigabatrin Drugs 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Abstract
本申请涉及医药给药技术领域,具体公开了一种用于脑部疾病诊断和治疗的微针系统及其制备方法。一种用于脑部疾病诊断和治疗的微针系统包括活性药物脂质体0.1‑10份;分散剂1‑10份;其中,所述活性药物脂质体包括以下原料制成:活性药物0.1‑10份;磷脂10‑100份;胆固醇10‑100份。其制备方法为:通过薄膜水化‑冻融‑均质法制得。本申请的一种用于脑部疾病诊断和治疗的微针系统,其具有改变现有用于脑部疾病治疗的微针需要手术植入的方式,采用经皮给药,无需手术且治疗效果良好的优点。
Description
技术领域
本申请涉及医学给药的技术领域,更具体地说,它涉及一种用于脑部疾病诊断和治疗的微针系统及其制备方法。
背景技术
脑部疾病是一类发生在脑部的异质性神经和精神障碍,会引起患者严重的个人痛苦和经济损失。在各类脑部疾病中,以多形胶质母细胞瘤为代表的脑部肿瘤和以阿尔茨海默病及帕金森病为代表的脑部神经退行性疾病,尤其受到人们的关注。其全球患病人数较高,且病情造成的后果较严重,而现有的药物诊断和治疗效果并不理想。究其原因,大脑的天然防御系统血脑屏障(Blood Brain Barrier,BBB)在保护大脑免受有害物质侵害的同时,也限制了大部分成像探针和药物分子进入,严重影响了脑胶质瘤的诊断和治疗。
淋巴系统是独立于血液循环系统的另一套液体网状循环系统,它遍布人体大部分组织,协助清除间质中的代谢废物,以维持体液稳态,并发挥免疫应答及免疫监视作用。虽然脑膜淋巴管在发育时间和形态上存在一定的特殊性,但与外周淋巴管类似,它们是高表达成熟淋巴内皮细胞的标志物。脑淋巴系统,其功能不仅仅局限于对代谢产物的清除,对于脑脊液循环的影响同样不可忽视。2020年1月15日耶鲁大学医学院Akiko Iwasaki教授团队在Nature杂志上发表文章揭示血管内皮生长因子C(VEGF-C)促进颈深淋巴结中CD8T细胞引流至大脑中,并促进CD8T细胞启动,迁移至肿瘤部位,快速清除胶质母细胞瘤,发挥持久的抗肿瘤免疫记忆反应。但是在将颈深淋巴结进行结扎后,VEGF-C的这种抗肿瘤作用就消失了,这就表明VEGF-C对胶质母细胞瘤的清除作用需要淋巴引流至颈深部淋巴结。因此,开发安全高效的新型经颈深淋巴结的脑部药物递送策略,成为中枢神经系统领域的重要研究目标。
微针能够以微创无痛的方式克服角质层障碍,可有效促进药物分子的经皮渗透,尤其是在大分子药物的经皮递送方面有着显著的效果。在21世纪初,逐渐有实验证明微针可大幅度提高胰岛素的经皮递送。随着材料的日益丰富,越来越多的材料被开发用于胰岛素微针的制备。其中,可溶胰岛素微针因可达到与注射相近的给药效果,而得到了广泛的关注。中科院上海微系统所陶虎研究员团队与复旦大学附属华山医院神经外科毛颖教授团队合作,针对脑胶质瘤治疗,开发出基于蚕丝蛋白的异质、异构、可降解微针贴片。该微针贴片可同时携带三种药物,药物的释放顺序和周期能够匹配临床用药规范的差异性要求,具备术中快速止血、术后长期化疗抑制肿瘤细胞、按需定时启动靶向抑制血管生成等关键功能。在切除肿瘤的手术过程中,将该贴片原位植入到瘤腔内,待其释放药物后可完全降解消失,无需二次手术取出,且降解产物不会引起免疫炎症反应。这种颅内局部给药的方式不仅解决了血脑屏障对药物分子的阻碍问题,还降低了常规全身大剂量给药的毒副作用。在动物实验中,与空白组和注射组相比,采用蚕丝蛋白载药微针贴片的治疗组有效抑制了肿瘤体积,显著延长了小鼠生存时间。美国约翰霍普金斯大学李兴德教授报告了一种超小型(外径580μm)治疗性深部脑微针,与800nm光学相干断层成像与激光切除相结合。通过小鼠脑显微结构的体内超高分辨率(轴向1.7μm,横向5.7μm)、高速(每秒20帧)容积成像和光衰减系数的测定,证明了该方法的有效性。通过在小鼠深部脑的体内肿瘤可视化(成像深度为1.23mm)和有效的组织切除(350mw功率的1448nm连续波激光)进一步证明了其转化潜能。
然而以上的这些方法都需要将微针通过手术的方式植入脑组织,众所周知,手术无论大小均存在一定风险,更何况是对于脑部手术,风险更是增加了不少。故发明人认为相关技术中关于脑部疾病治疗位置的给药方式单一,且风险较高的缺陷。
发明内容
为了改善相关技术中对于脑部疾病诊断和治疗的微针给药方式单一,以及手术风险高的缺陷,本申请提供一种用于脑部疾病诊断和治疗的微针系统及其制备方法。
第一方面,本申请提供一种用于脑部疾病诊断和治疗的微针系统,采用如下的技术方案:
一种用于脑部疾病诊断和治疗的微针系统,包括以下重量份原料制成:
活性药物脂质体0.1-10份;
分散剂1-10份;
其中,所述活性药物脂质体包括以下原料制成:
活性药物0.1-10份;
磷脂10-100份;
胆固醇10-100份。
通过采用以上技术方案,负载有活性药物脂质体的微针可成功的将活性药物脂质体通过颈深淋巴结递送到脑部,发挥治疗效果。可以避免肠胃环境对药效的干扰和肝脏“首过效应”,维持恒定的最佳血药浓度或生理效应,延长有效作用时间,减少用药次数,患者可自主给药,依从性较好。
可选的,所述一种用于脑部疾病诊断和治疗的微针系统还包括NK细胞膜蛋白。
通过采用上述技术方案,NK细胞为自然杀伤细胞(Natural Killer cell,NK),是机体重要的免疫细胞,不仅与抗肿瘤、抗病毒感染和免疫调节有关,而且在某些情况下参与超敏反应和自身免疫性疾病的发生;采用其膜蛋白进行仿生,能够有效提高活性药物脂质体进入脑部细胞的速率,从而快速发挥效果。
可选的,所述活性药物脂质体与NK细胞膜蛋白的质量比为300:1。
可选的,所述活性药物脂质体与NK细胞膜蛋白通过均质法制得仿生活性药物脂质体,所述均质法的具体操作为:
1)在20psi的气压下,进行3-10次均质操作;
2)调节气压至40psi,继续3-10次均质操作即得仿生活性药物脂质体。
通过采用上述技术方案,通过高压均质法使得活性药物脂质体与NK细胞膜蛋白,使得最终得到的仿生活性药物脂质体的粒径大小合适,且均匀,表面光滑无结晶。
可选的,所述活性药物包括水溶性活性药物和脂溶性活性药物;当活性药物为脂溶性活性药物时,所述脂溶性活性药物脂质体的制备包括以下步骤:
S1脂溶性活性药物前处理以及脂溶性活性药物载体的制备,
脂溶性活性药物载体的制备:取10-100份的磷脂和10-100份的胆固醇,溶于氯仿中得混合液I备用;
脂溶性药物前处理方法为:取0.1-10份的脂溶性活性药物,溶于无水甲醇或者乙醚中得混合液II备用;
S2旋蒸混合液,
将混合液I和混合液II混合,然后蒸干得混合物;
S3活性药物脂质体的制备,
1)使用PBS缓冲液冲洗混合物,然后在液氮-65℃下进行冻融,循环4-8次得到活性药物脂质体溶液;
2)进行透析或先进行挤压过滤后再进行透析制得活性药物脂质体,置于4℃下避光保存;
当活性药物为水溶性活性药物时,所述水溶性活性药物脂质体的制备包括以下步骤:
S1水溶性活性药物载体的制备:取10-100份的磷脂和10-100份的胆固醇,溶于氯仿中得混合液I备用;
S2旋蒸混合液:将混合液I旋蒸蒸干得混合物;
S3活性药物脂质体的制备,
1)使用PBS缓冲液冲洗混合物并加入0.1-10份的水溶性活性药物,使其充分溶解,然后在液氮-65℃下进行冻融,循环4-8次得到活性药物脂质体溶液;
2)进行透析或先进行挤压过滤后再进行透析制得活性药物脂质体,置于4℃下避光保存。
通过采用上述技术方案,先使用氯仿将磷脂和胆固醇进行溶解,使用无水甲醇和乙醚溶解活性药物,然后混合,能够使得活性药物充分与磷脂、胆固醇混合,使得活性药物能够均匀分布在脂质体中,其次使用PBS冲洗混合物,是为了将混合物从容器壁上冲洗脱落,S3的最后一步进行透析是为了将游离的活性药物去除;其中脂溶性药物如姜黄素、尼莫地平、氟桂利嗪、川芎嗪、罂粟碱、长春西汀等,需要使用无水甲醇进行溶解,然后使其充分分散在脂质体内,如水溶性药物如,倍他司汀、丙戊酸钠、苯妥英钠等,则直接使用PBS缓冲液进行溶解即可。
优选的,所述活性药物包括水溶性活性药物和脂溶性活性药物;当活性药物为脂溶性活性药物时,所述脂溶性活性药物脂质体的制备包括以下步骤:
S1脂溶性活性药物前处理以及脂溶性活性药物载体的制备,
脂溶性活性药物载体的制备:取50份的磷脂和25份的胆固醇,溶于氯仿中得混合液I备用;
脂溶性药物前处理方法为:取0.25份的脂溶性活性药物,溶于无水甲醇或者乙醚中得混合液II备用;
S2旋蒸混合液,
将混合液I和混合液II混合,然后蒸干得混合物;
S3活性药物脂质体的制备,
1)使用PBS缓冲液冲洗混合物,然后在液氮-65℃下进行冻融,循环6次得到活性药物脂质体溶液;
2)进行透析或先进行挤压过滤后再进行透析制得活性药物脂质体,置于4℃下避光保存;
当活性药物为水溶性活性药物时,所述水溶性活性药物脂质体的制备包括以下步骤:S1水溶性活性药物载体的制备:取50份的磷脂和25份的胆固醇,溶于氯仿中得混合液I备用;
S2旋蒸混合液:将混合液I旋蒸蒸干得混合物;
S3活性药物脂质体的制备,
1)使用PBS缓冲液冲洗混合物并加0.25份水溶性活性药物,使水溶性活性药物充分溶解,然后在液氮-65℃下进行冻融,循环5次得到活性药物脂质体溶液;
2)进行透析或先进行挤压过滤后再进行透析制得活性药物脂质体,置于4℃下避光保存。
可选的,所述磷脂为大豆卵磷脂。
可选的,所述S3中的步骤2)中的挤压操作具体为:依次采用装有不同孔径的滤膜的脂质体挤压器反复挤压20次,且滤膜孔径依次减小。
可选的,所述滤膜为聚碳酸酯膜,所述聚碳酸酯膜的孔径为200nm,100nm和50nm。
具体的,所述S3中的步骤2)中的挤压操作为,依次采用装有孔径为200nm,100nm和50nm的聚碳酸酯膜的脂质体挤压器进行挤压过滤,挤压过滤次数分别为20次。
通过采用上述技术方案,通过反复的挤压过滤,使得脂质体内的颗粒粉碎,依次通过200nm、100nm以及50nm的滤膜,使得脂质体的粒径均一,最终得到粒径为50nm的活性药物脂质体。
可选的,所述分散剂为透明质酸钠、透明质酸、葡聚糖或者聚乙二醇(PEG)中的一种或多种的组合。
优选的,所述分散剂为透明质酸钠和葡聚糖。
可选的,所述活性药物为姜黄素、尼莫地平、氟桂利嗪、倍他司汀、川芎嗪、丁苯酞、罂粟碱、银杏叶提取物、长春西汀、富马酸喹硫平、奥氮平、西酞普兰、阿普唑仑、奥沙西泮(去甲羟安定)、劳拉西泮(罗拉)、三唑仑(海乐神)、美多芭、泰舒达、森福罗、息宁、安坦、司来吉兰、雷沙吉兰、托卡朋、罗匹尼罗,安坦、氨溴索,珂丹,金刚烷胺,卡马西平、丙戊酸钠、苯妥英钠、加巴喷丁、拉莫三嗪、奥卡西平、苯巴比妥、托吡酯、氨己烯酸、左乙拉西坦、氯硝西泮、地西泮、马来酸咪达唑仑、乙琥胺、扑痫酮、唑尼沙胺、普瑞巴林、瑞替加滨中的一种。
第二方面,本申请提供一种用于脑部疾病诊断和治疗的微针系统的制备方法,采用如下的技术方案:一种用于脑部疾病诊断和治疗的微针系统的制备方法,包括以下制备步骤:
1)取以上制得的活性药物脂质体或者仿生活性药物脂质体进行冻干,得到白色粉末;
2)取1)中0.1-10份的活性药物脂质体或仿生活性药物脂质体以及1-10份的分散剂分散于水中,搅拌至充分溶解得基质液;
3)将2)中得到的基质液注入微针模具中,进行离心倒转使得基质液均匀分布在模具中,并充满模具中的微针针尖部分;
4)再取1-10份的分散剂分散于水中,得分散液;然后将分散液加入步骤3)中微针针尖中,离心后干燥,得活性药物脂质体微针或者仿生活性药物脂质体微针;
5)在微针基底背面贴上压敏胶被衬,脱模,即得活性药物脂质体微针贴片或仿生活性药物脂质体微针贴片。
优选的,一种用于脑部疾病诊断和治疗的微针系统的制备方法,包括以下制备步骤:
1)取以上制得的活性药物脂质体或者仿生活性药物脂质体进行冻干,得到白色粉末;
2)取1)中2份的活性药物脂质体或仿生活性药物脂质体以及4份的分散剂分散于水中,搅拌至充分溶解得基质液;
3)将2)中得到的基质液注入微针模具中,进行离心倒转使得基质液均匀分布在模具中,并充满模具中的微针针尖部分;
4)再取1份的葡聚糖和2份的透明质酸钠分散于水中,得分散液;然后将分散液加入步骤3)中微针针尖中,离心后干燥,得活性药物脂质体微针或者仿生活性药物脂质体微针;
5)在微针基底背面贴上压敏胶被衬,脱模,即得活性药物脂质体微针贴片或仿生活性药物脂质体微针贴片。
可选的,所述步骤4)中干燥温度为4℃,干燥时间为1-100h;优选的,干燥时间为24h。
综上所述,本申请具有以下有益效果:本申请提高的一种用于脑部疾病诊断和治疗的微针系统无需动手术,是一种工艺简单,安全性高,无需长期贴敷的可植入型缓释微针。采用经皮给药(贴于头部或颈部),使药物经过颈部深层淋巴结及脑膜淋巴管,绕过血脑屏障到达脑组织,发挥治疗效果。
附图说明
图1是本申请公开的一种用于脑部疾病诊断和治疗的微针系统的姜黄素脂质体的TEM图;
图2是本申请公开的一种用于脑部疾病诊断和治疗的微针系统的姜黄素脂质体的粒径图;
图3是本申请实施例1中小鼠脑切片的姜黄素分布图;
图4是本申请应用例1-3的关于不同时间点姜黄素入脑的效率对比表。
具体实施方式
本发明的目的是为了克服现有技术的上述不足,提供一种体外脑部或颈部微针贴片,用于治疗脑部疾病。该方法将治疗脑部疾病的活性药物负载于微针中,并探究了负载有活性药物的微针的经皮给药效果(贴于头部或颈部)。本申请实施例中的活性药物以姜黄素为例,在其他的实施例中,活性药物还可以是尼莫地平、氟桂利嗪、倍他司汀、川芎嗪、丁苯酞、罂粟碱、银杏叶提取物、长春西汀、富马酸喹硫平、奥氮平、西酞普兰、阿普唑仑、奥沙西泮(去甲羟安定)、劳拉西泮(罗拉)、三唑仑(海乐神)、美多芭、泰舒达、森福罗、息宁、安坦、司来吉兰、雷沙吉兰、托卡朋、罗匹尼罗,安坦、氨溴索,珂丹,金刚烷胺,卡马西平、丙戊酸钠、苯妥英钠、加巴喷丁、拉莫三嗪、奥卡西平、苯巴比妥、托吡酯、氨己烯酸、左乙拉西坦、氯硝西泮、地西泮、马来酸咪达唑仑、乙琥胺、扑痫酮、唑尼沙胺、普瑞巴林、瑞替加滨等治疗脑部疾病的药物。
结果显示,负载有姜黄素脂质体的微针可成功的将姜黄素脂质体通过颈深淋巴结递送到脑部,发挥治疗效果。本发明对于推动临床治疗脑部疾病的微针的应用转化具有重要意义,为脑部疾病的治疗提供新方法和新技术。
以下结合附图1至附图4和实施例对本申请作进一步详细说明。予以特殊说明的是:以下实施例中未注明具体条件者按照常规条件或制造商建议的条件进行,以下实施例中所用原料除特殊说明外均可来源于普通市售。
姜黄素脂质体的制备例
制备例1
S1姜黄素溶解以及姜黄素载体的制备,
姜黄素载体的制备:取50mg磷脂和25mg胆固醇,溶于2ml的氯仿中得混合液I备用;
姜黄素前处理:取0.25mg姜黄素,溶于2ml的无水甲醇中得混合液II备用;
S2旋蒸混合液,将混合液I和混合液II混合于圆底烧瓶中,然后置于旋蒸仪(型号是IKA-RV10)上进行旋蒸,旋蒸仪的转速为60rpm,温度为27℃,蒸干圆底烧瓶瓶壁上形成薄膜混合物;
S3姜黄素脂质体的制备,
1)使用5ml的PBS冲洗烧瓶壁上的薄膜混合物,使其完全脱落,然后在液氮-65℃下进行冻融,循环5次得到脂质体溶液;
2)使用装有聚碳酸酯膜的脂质体挤压器(型号是Avanti脂质体挤出器610023)反复挤压20次,并且依次过滤;其中聚碳酸酯膜的孔径为200nm、100nm和50nm;挤压过滤时所使用的滤膜孔径依次减小,以便得到的粒径均一的脂质体
3)最后透析制得姜黄素脂质体,置于4℃下避光保存。
制备例2-3,与制备例1的不同之处在于,所使用的原料用量不同,具体见下表。
仿生姜黄素脂质体的制备例
制备例4
取30mg制备例1所制得的姜黄素脂质体放入注射器中,然后向注射器中加入0.1mg的NK细胞膜蛋白。
打开高压均质机气泵,设置压力为20psi,打开均质阀填充压力;将装有样品的注射器装入均质机中,均质操作重复5次,然后将压力设置为40psi,继续进行均质操作,并重复5次,最后得到仿生姜黄素脂质体。
实施例
实施例1
1)取制备例1制得的姜黄素脂质体进行冻干,得到白色粉末;
2)取1)中2g的姜黄素脂质体或仿生姜黄素脂质体以及4g的透明质酸钠分散于4ml水中,搅拌至充分溶解得基质液;
3)将2)中得到的基质液注入微针模具中,进行离心倒转6次使得基质液均匀分布在模具中,并充满模具中的微针针尖部分;
4)再取1g的葡聚糖和2g的透明质酸钠分散于7ml的水中,得分散液;然后将分散液加入步骤3)中微针针尖中,离心后干燥24h,得姜黄素脂质体微针;
5)在微针基底背面贴上压敏胶被衬,脱模,即得姜黄素脂质体微针贴片。
实施例2-3
实施例2-3与实施例1的不同之处在于,所使用的原料的用量不同,具体如下表所示。
实施例4
本实施例与实施例1的不同之处在于,所使用的是制备例4制得的仿生姜黄素脂质体。将所得到的仿生姜黄素脂质体进行电镜扫描,得如图1所示的仿生姜黄素脂质体的TEM图,从TEN图可以看出,仿生姜黄素脂质体的粒径大约是50nm,分散性比较好。另外通过粒径分析仪,测定仿生姜黄素脂质体的粒径分布,如图2所示,仿生姜黄素脂质体的水合粒径大约是50nm,颗粒比较均匀。
应用例
应用例1:首先取实验小鼠,并脱掉小鼠颈部和头部的毛;然后将实施例1制备的姜黄素脂质体微针贴片贴于小鼠颈部(姜黄素脂质体组);最后采用小动物活体成像系统(IVIS)跟踪了姜黄素在小鼠脑部的分布,如图3和图4所示。
应用例2:与应用例1的不同之处在于,是将实施例4制备的仿生姜黄素脂质体微针贴片贴于小鼠颈部(仿生姜黄素脂质体组),采用小动物活体成像系统(IVIS)跟踪了姜黄素在小鼠脑部的分布,如图4所示。
应用例3:采用制备例1所得的姜黄素脂质体,将其注射至小鼠的尾部静脉中(尾静脉组),然后采用小动物活体成像系统(IVIS)跟踪了姜黄素在小鼠脑部的分布,如图4所示。
其他应用,还可以将采用本申请的制备方法制备的姜黄素脂质体或仿生姜黄素脂质体做成凝胶贴于头部或颈部,或采用超声和皮下注射等方法导入头部或颈部。
结合实施例以及应用例,图1-图4,可以看出采用本申请提供的一种微针系统的制备方法制备的微针贴片,结果显示,负载有姜黄素脂质体或仿生姜黄素脂质体的微针可成功的将姜黄素脂质体或仿生将黄石脂质体通过颈深淋巴结递送到脑部,发挥治疗效果。本发明对于推动临床姜黄素脂质体的微针的应用转化具有重要意义,为脑部疾病的治疗提供新方法和新技术。相比于传统的脑部疾病治疗方法,无需动手术,降低了治疗风险,是一种工艺简单,安全性高,无需长期贴敷的可植入型缓释微针。可以避免肠胃环境对药效的干扰和肝脏“首过效应”,维持恒定的最佳血药浓度或生理效应,延长有效作用时间,减少用药次数,患者可自主给药,依从性较好其原理是采用经皮给药(贴于头部或颈部),使药物经过颈部深层淋巴结及脑膜淋巴管,绕过血脑屏障到达脑组织,发挥治疗效果。
本具体实施例仅仅是对本申请的解释,其并不是对本申请的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本申请的权利要求范围内都受到专利法的保护。
Claims (10)
1.一种用于脑部疾病诊断和治疗的微针系统,其特征在于,包括以下重量份的原料制成:
活性药物脂质体0.1-10份;
分散剂1-20份;
其中,所述活性药物脂质体包括以下重量份的原料制成:
活性药物0.1-10份
磷脂10-100份;
胆固醇10-100份。
2.根据权利要求1所述的一种用于脑部疾病诊断和治疗的微针系统,其特征在于,所述一种用于脑部疾病诊断和治疗的微针系统还包括NK细胞膜蛋白。
3.根据权利要求2所述的一种用于脑部疾病诊断和治疗的微针系统,其特征在于,所述活性药物脂质体与NK细胞膜蛋白的质量比为300:1。
4.根据权利要求2-3所述的一种用于脑部疾病诊断和治疗的微针系统,其特征在于,所述活性药物脂质体与NK细胞膜蛋白通过均质法制得仿生活性药物脂质体,所述均质法的具体操作为:1)在20psi的气压下,进行3-10次均质操作;2)调节气压至40psi,继续3-10次均质操作即得仿生活性药物脂质体。
5.根据权利要求1-3任一项所述的部疾病诊断和治疗的微针系统,其特征在于,所述活性药物包括水溶性活性药物和脂溶性活性药物;当活性药物为脂溶性活性药物时, 所述脂溶性活性药物脂质体的制备包括以下步骤:
S1脂溶性活性药物前处理以及脂溶性活性药物载体的制备,
脂溶性活性药物载体的制备:取10-100份的磷脂和10-100份的胆固醇,溶于氯仿中得混合液I备用;
脂溶性药物前处理方法为:取0.1-10份的脂溶性活性药物,溶于无水甲醇或者乙醚中得混合液II备用;
S2旋蒸混合液,
将混合液I和混合液II混合,然后蒸干得混合物;
S3活性药物脂质体的制备,
1)使用PBS缓冲液冲洗混合物,然后在液氮-65℃下进行冻融,循环4-8次得到活性药物脂质体溶液;
2)进行透析或先进行挤压过滤后再进行透析制得活性药物脂质体,置于4℃下避光保存;
当活性药物为水溶性活性药物时, 所述水溶性活性药物脂质体的制备包括以下步骤:
S1水溶性活性药物载体的制备:取10-100份的磷脂和10-100份的胆固醇,溶于氯仿中得混合液I备用;
S2旋蒸混合液:将混合液I旋蒸蒸干得混合物;
S3活性药物脂质体的制备,
1)使用PBS缓冲液冲洗混合物并加0.1-10份水溶性活性药物,使水溶性活性药物充分溶解,然后在液氮-65℃下进行冻融,循环4-8次得到活性药物脂质体溶液;
2)进行透析或先进行挤压过滤后再进行透析制得活性药物脂质体,置于4℃下避光保存。
6.根据权利要求5所述的一种用于脑部疾病诊断和治疗的微针系统,其特征在于,所述S3还包括挤压过滤,所述挤压过滤操作具体为:依次采用装有不同孔径滤膜的脂质体挤压器反复挤压20次,且滤膜孔径依次减小。
7.根据权利要求5所述的一种用于脑部疾病诊断和治疗的微针系统,其特征在于,所述滤膜为聚碳酸酯膜,所述聚碳酸酯膜的孔径为200nm,100nm和50nm。
8.根据权利要求1所述的一种用于脑部疾病诊断和治疗的微针系统,其特征在于,所述分散剂为透明质酸钠、透明质酸、葡聚糖或者PEG中的一种或多种的组合。
9.根据权利要求1所述的一种用于脑部疾病诊断和治疗的微针系统,其特征在于,所述活性药物为治疗脑部疾病的药物,具体为姜黄素、尼莫地平、氟桂利嗪、倍他司汀、川芎嗪、丁苯酞、罂粟碱、银杏叶提取物、长春西汀、富马酸喹硫平、奥氮平、西酞普兰、阿普唑仑、奥沙西泮(去甲羟安定)、劳拉西泮(罗拉)、三唑仑(海乐神)、美多芭、泰舒达、森福罗、息宁、安坦、司来吉兰、雷沙吉兰、托卡朋、罗匹尼罗,安坦、氨溴索,珂丹,金刚烷胺,卡马西平、丙戊酸钠、苯妥英钠、加巴喷丁、拉莫三嗪、奥卡西平、苯巴比妥、托吡酯、氨己烯酸、左乙拉西坦、氯硝西泮、地西泮、马来酸咪达唑仑、乙琥胺、扑痫酮、唑尼沙胺、普瑞巴林、瑞替加滨中的一种。
10.权利要求1-9所述的一种用于脑部疾病诊断和治疗的微针系统的制备方法,其特征在于,包括以下制备步骤:
1)取以上制得的活性药物脂质体或者仿生活性药物脂质体进行冻干,得到白色粉末;
2)取1)中0.1-10份的活性药物脂质体或仿生活性药物脂质体以及1-10份的分散剂分散于水中,搅拌至充分溶解得基质液;
3)将2)中得到的基质液注入微针模具中,进行离心倒转使得基质液均匀分布在模具中,并充满模具中的微针针尖部分;
4)再取1-10份的分散剂分散于水中,得分散液;然后将分散液加入步骤3)中微针针尖中,离心后干燥,得活性药物脂质体微针或者仿生活性药物脂质体微针;
5)在微针基底背面贴上压敏胶被衬,脱模,即得活性药物脂质体微针贴片或仿生活性药物脂质体微针贴片。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210589807.8A CN114948852A (zh) | 2022-05-26 | 2022-05-26 | 一种用于脑部疾病诊断和治疗的微针系统及其制备方法 |
PCT/CN2022/101279 WO2023226136A1 (zh) | 2022-05-26 | 2022-06-24 | 一种用于脑部疾病诊断和治疗的微针系统及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210589807.8A CN114948852A (zh) | 2022-05-26 | 2022-05-26 | 一种用于脑部疾病诊断和治疗的微针系统及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114948852A true CN114948852A (zh) | 2022-08-30 |
Family
ID=82955668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210589807.8A Pending CN114948852A (zh) | 2022-05-26 | 2022-05-26 | 一种用于脑部疾病诊断和治疗的微针系统及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114948852A (zh) |
WO (1) | WO2023226136A1 (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103637988A (zh) * | 2013-09-11 | 2014-03-19 | 浙江中医药大学 | 一种姜黄素长循环脂质体的制备方法 |
CN106176609A (zh) * | 2016-08-22 | 2016-12-07 | 李因传 | 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用 |
CN107050465A (zh) * | 2017-01-17 | 2017-08-18 | 中国药科大学 | 一种用于脑部疾病诊疗的功能性姜黄素纳米药物及其应用 |
CN109077994A (zh) * | 2018-09-04 | 2018-12-25 | 南京工业大学 | 小分子水凝胶-纳米粒复合药物载体及其在皮肤/粘膜给药系统中的应用 |
CN112716899A (zh) * | 2019-10-11 | 2021-04-30 | 复旦大学 | 一种防治主动脉夹层的仿生纳米药物及其制备方法 |
CN112823811A (zh) * | 2019-11-18 | 2021-05-21 | 深圳先进技术研究院 | 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法 |
US20210252168A1 (en) * | 2018-06-14 | 2021-08-19 | Fudan University | Amyloid b short peptide mediated brain targeted delivery system, preparation method therefor and use thereof |
CN114432230A (zh) * | 2022-02-28 | 2022-05-06 | 浙江工业大学 | 一种经皮递送脂质体治疗银屑病的微针及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10525246B2 (en) * | 2006-12-22 | 2020-01-07 | Nanomed Skincare, Inc. | Microdevice and method for transdermal delivery and sampling of active substances |
JP5879126B2 (ja) * | 2008-10-07 | 2016-03-08 | ジン・トゥオJIN Tuo | 相転移ポリマーマイクロニードル |
WO2018187240A1 (en) * | 2017-04-03 | 2018-10-11 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
CN108478521A (zh) * | 2018-05-02 | 2018-09-04 | 苏宇雄 | 一种载有脂质体顺铂纳米颗粒的可溶解微针及其制备方法 |
CN111759794B (zh) * | 2020-07-14 | 2023-07-21 | 中山大学 | 一种治疗黑色素瘤的微针及其制备方法 |
-
2022
- 2022-05-26 CN CN202210589807.8A patent/CN114948852A/zh active Pending
- 2022-06-24 WO PCT/CN2022/101279 patent/WO2023226136A1/zh unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103637988A (zh) * | 2013-09-11 | 2014-03-19 | 浙江中医药大学 | 一种姜黄素长循环脂质体的制备方法 |
CN106176609A (zh) * | 2016-08-22 | 2016-12-07 | 李因传 | 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用 |
CN107050465A (zh) * | 2017-01-17 | 2017-08-18 | 中国药科大学 | 一种用于脑部疾病诊疗的功能性姜黄素纳米药物及其应用 |
US20210252168A1 (en) * | 2018-06-14 | 2021-08-19 | Fudan University | Amyloid b short peptide mediated brain targeted delivery system, preparation method therefor and use thereof |
CN109077994A (zh) * | 2018-09-04 | 2018-12-25 | 南京工业大学 | 小分子水凝胶-纳米粒复合药物载体及其在皮肤/粘膜给药系统中的应用 |
CN112716899A (zh) * | 2019-10-11 | 2021-04-30 | 复旦大学 | 一种防治主动脉夹层的仿生纳米药物及其制备方法 |
CN112823811A (zh) * | 2019-11-18 | 2021-05-21 | 深圳先进技术研究院 | 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法 |
WO2021098686A1 (zh) * | 2019-11-18 | 2021-05-27 | 深圳先进技术研究院 | 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法 |
CN114432230A (zh) * | 2022-02-28 | 2022-05-06 | 浙江工业大学 | 一种经皮递送脂质体治疗银屑病的微针及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2023226136A1 (zh) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Al-Japairai et al. | Current trends in polymer microneedle for transdermal drug delivery | |
Chen et al. | Preparation, properties and challenges of the microneedles-based insulin delivery system | |
CN109528695B (zh) | 一种治疗类风湿性关节炎的微针透皮给药贴片及其制备方法 | |
CA2795995C (en) | Microneedle assembly formulation for skin treatment | |
CN108785244B (zh) | 一种担载疏水药物的可溶性微针及其制备方法 | |
CN105078880A (zh) | 一种用于多肽和蛋白质类药物透皮给药的高分子可溶微针及其制备方法 | |
JP2001501931A (ja) | 蛋白質安定化した薬理学的活性薬剤、その製造方法およびその使用方法 | |
Wu et al. | One injection for one-week controlled release: In vitro and in vivo assessment of ultrasound-triggered drug release from injectable thermoresponsive biocompatible hydrogels | |
Huang et al. | Research progress on cosmetic microneedle systems: Preparation, property and application | |
Long et al. | Microneedles for in situ tissue regeneration | |
Jiang et al. | The progress of fabrication designs of polymeric microneedles and related biomedical applications | |
CN113975249A (zh) | Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用 | |
Mbituyimana et al. | Microneedle-based cell delivery and cell sampling for biomedical applications | |
JP2023502519A (ja) | 免疫刺激薬物送達用マイクロニードルパッチ | |
Kenchegowda et al. | Tiny titans-unravelling the potential of polysaccharides and proteins based dissolving microneedles in drug delivery and theranostics: a comprehensive review | |
CN110840823B (zh) | 一种传递体复合自溶微针及其制备方法 | |
CN114948852A (zh) | 一种用于脑部疾病诊断和治疗的微针系统及其制备方法 | |
Naveen et al. | Prospection of fabrication techniques and material selection of microneedles for transdermal drug delivery: An update on clinical trials | |
Liu et al. | Stimuli-responsive polymer microneedles: A rising transdermal drug delivery system and its applications in biomedical | |
Bodkhe et al. | A review of microneedles–elevation to TDDS approach and function in management of psoriasis | |
Samanci et al. | Enhancing Skin Penetration: The Role of Microneedles | |
Guo et al. | Advances in Formulations of Microneedle System for Rheumatoid Arthritis Treatment | |
Liu et al. | Recent advances and perspectives of microneedles as transdermal delivery vehicles for analgesic medications | |
CN108619080B (zh) | 载有纳米材料包裹促排卵药物的微针给药系统及制备方法 | |
CN109925297A (zh) | 含乌头碱的经皮给药系统及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |